Se connecter S'abonner en ligne
  • Infos sociétés
  • Infos OPCVM
  • Alertes e-mail
  • Notre offre
 Langues  Par thème  Par secteur d'activité  Par pays
Adolore Biotherapeutics, Inc. [0]   
[16/05/2024]

Adolore Biotherapeutics, Inc. : Adolore BioTherapeutics Announces Publication Demonstrating Carbonic Anhydrase-8 Gene Therapy (rdHSV-CA8) Decreased Pain-Sensing Neuronal Excitability by Activating Kv7 Voltage-Gated Potassium Channels

Findings highlight the advantages of Adolores approach for the delivery of proprietary gene therapy directly to specialized painsensing peripheral nerves nociceptors that mediate profound analgesia with the potential to address the great unmet need for nonopioid chronic pain therapiesData further supports the clinicaltranslational value of Adolores proprietary nonopioid analgesics for treating... Lire le communiqué
 
Adolore Biotherapeutics, Inc. [0]   
[04/03/2024]

Adolore Biotherapeutics, Inc. : Adolore BioTherapeutics Announces Issuance of First U.S. Patent Covering CA8* Gene Therapies to Treat Chronic Pain

Patent and CA8 gene therapy technology licensed by Adolore BioTherapeutics from the University of MiamiCompany advancing development of rdHSVCA8 gene therapy for the treatment of chronic osteoarthritis OA knee pain toward an INDDELRAY BEACH, FL / ACCESSWIRE / March 4, 2024 / Adolore BioTherapeutics "Adolore" or the "Company", a biotechnology company focused on developing... Lire le communiqué
 
Adolore Biotherapeutics, Inc. [0]   
[30/01/2024]

Adolore Biotherapeutics, Inc. : Adolore BioTherapeutics to Present at the 5th Annual National Institutes of Health (NIH) HEAL Initiative Scientific Meeting

DELRAY BEACH, FL / ACCESSWIRE / January 30, 2024 / Adolore BioTherapeutics "Adolore" or the "Company", a biotechnology company focused on developing breakthrough opioidfree gene therapy treatments for chronic pain, today announced that Roy C. Levitt, MD, the Companys founder and Executive Chairman, Clinical Professor, University of Miami, and Principal Investigator of a NIH,... Lire le communiqué
 
Adolore Biotherapeutics, Inc. [0]   
[05/12/2023]

Adolore Biotherapeutics, Inc. : Adolore BioTherapeutics Presents Promising Preclinical Data Supporting Its Innovative Gene Therapy to Treat Chronic Pain

Innovative rdHSVbased CA8 gene therapy demonstrates preclinical proofofconcept as a diseasemodifying longacting local analgesic to replace opioids in chronic osteoarthritis OA knee pain managementDELRAY BEACH, FL / ACCESSWIRE / December 5, 2023 / Adolore BioTherapeutics "Adolore" or the "Company", a biotechnology company focused on developing breakthrough opioidfree gene... Lire le communiqué
 
Adolore Biotherapeutics, Inc. [0]   
[11/10/2023]

Adolore Biotherapeutics, Inc. : Adolore BioTherapeutics to Participate at the Virtual Investor Ask the CEO Conference

Live moderated webcast with Roelof Rongen, Chief Executive Officer of Adolore BioTherapeutics on Wednesday, October 25th at 3:00 PM ETDELRAY BEACH, FL / ACCESSWIRE / October 11, 2023 / Adolore BioTherapeutics "Adolore" or the "Company", a company focused on developing breakthrough opioidfree gene therapy treatments for chronic pain, today announced that Roelof Rongen,... Lire le communiqué
 
Adolore Biotherapeutics, Inc. [0]   
[03/10/2023]

Adolore Biotherapeutics, Inc. : NIN/NINDS HEAL Program Grants Prestigious UH3 Award to the University of Miami, Principal Investigator Roy C. Levitt M.D, to Fund Clinical Development of Adolore BioTherapeutics’ Gene Therapy Program for the Treatment of Chronic Osteoarthritis Knee Pain

UH3 Award follows the successful completion of an initial NIH/NINDS HEAL UG3 grant for which all preclinical milestones were metThis NIH/NINDS HEAL UH3 Award will support all formal preclinical GLP/GMP/GCP development work through a firstinhuman study in patients, undertaken in collaboration with Adolore BioTherapeutics and expected to commence in 2026DELRAY BEACH, FL / ACCESSWIRE / October 3,... Lire le communiqué
 


Vidéos
Gestionnaires,
Emetteurs,
Ma sélection
Les communiqués les plus lus de Adolore...